IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of IMUNON's management team will also be conducting in-person one-on-one meetings with investors September 8 - 10, 2025.

Read more at globenewswire.com